Spotlight -
In-person and virtual events just for HCPs
CME Opportunities
News
Article
March 7, 2025
Author(s):
Fact checked by:
Conference|PER® Miami Breast Cancer Conference
The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Subscribe Now!
Related Videos
Continued Advances and Treatment Sequencing for HR+/HER2– Breast CancerImpact of ADC Toxicities and Clinical Decision-Making for mBCDr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLLDr Jain on Existing Challenges Within the TNBC Treatment ParadigmSABCS Highlights and Future Directions in the Treatment of Breast CancerEmerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast CancerDr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast CancerADCs: Recent Data of Dato-DXd from TROPION-Breast01Clinical Developments of Antibody-Drug Conjugates (ADCs) in HR+/HER2– mBCDr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Related Content
View More
ConferenceBreast Cancer
March 7th 2025
Ribociclib Efficacy Is Maintained With Dose Reductions in Hormone Receptor+/HER2-Negative Early Breast Cancer
January 1st 2025
DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
March 5th 2025
Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward
September 11th 2024
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
March 3rd 2025
TNBC Awareness Day Emphasizes Progress in Treatment Strategies
March 1st 2025
The OncFive: Top Oncology Articles for the Week of 2/23
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info
2 Commerce Drive
Cranbury, NJ 08512
609-716-7777